If Mannkind was bought out, would be company be broken up?
Apr 22, 2014 18:56:54 GMT -5
brentie and ashiwi like this
Post by seanismorris on Apr 22, 2014 18:56:54 GMT -5
I've been reading articles on big pharma today and there have been some interesting developments (recently)...
See link:
www.fiercebiotech.com/story/gsk-punts-much-its-cancer-rd-work-big-pharma-swap-and-shop/2014-04-22
www.fiercebiotech.com/story/report-pfizer-pitches-101b-megamerger-struggling-astrazeneca/2014-04-20
Novartis ($NVS), GlaxoSmithKline ($GSK) and Eli Lilly ($LLY) have hammered out a pact to swap, sell and partner on a group of four different divisions, realigning the corporate and marketing landscape for each of the big three pharma players. The bulk of these multibillion-dollar transactions center around marketed therapies, with Novartis going deeper into oncology, GlaxoSmithKline expanding on its substantial work in vaccines and Lilly grabbing an animal health business it's been avidly interested in for some time. But there are some big implications here for the two leading players' R&D divisions as well.
--------
Eli Lilly is big in the diabetes space, but they 'like' animal health? Are they moving in another direction where there isn't the risk of patent cliffs?
The reason I find the mergers interesting is Eli Lilly has been mentioned as a possible partner/buyer of MNKD. Though I favor Novo Nordisk...
Also, Alfred is thought (rumored?) to have bought shares so he would have majority control. Did he prevent a hostile takeover?
Mannkind has been criticized for not having a partner by now, but it's obvious that a lot have been going on behind the scenes. So, the delay (in my mind) can be forgiven.
Now that these other mergers, etc. are out of the way, is it time for MNKD to make progress on the partner front? Or, do we still have to wait on the FDA?
See link:
www.fiercebiotech.com/story/gsk-punts-much-its-cancer-rd-work-big-pharma-swap-and-shop/2014-04-22
www.fiercebiotech.com/story/report-pfizer-pitches-101b-megamerger-struggling-astrazeneca/2014-04-20
Novartis ($NVS), GlaxoSmithKline ($GSK) and Eli Lilly ($LLY) have hammered out a pact to swap, sell and partner on a group of four different divisions, realigning the corporate and marketing landscape for each of the big three pharma players. The bulk of these multibillion-dollar transactions center around marketed therapies, with Novartis going deeper into oncology, GlaxoSmithKline expanding on its substantial work in vaccines and Lilly grabbing an animal health business it's been avidly interested in for some time. But there are some big implications here for the two leading players' R&D divisions as well.
--------
Eli Lilly is big in the diabetes space, but they 'like' animal health? Are they moving in another direction where there isn't the risk of patent cliffs?
The reason I find the mergers interesting is Eli Lilly has been mentioned as a possible partner/buyer of MNKD. Though I favor Novo Nordisk...
Also, Alfred is thought (rumored?) to have bought shares so he would have majority control. Did he prevent a hostile takeover?
Mannkind has been criticized for not having a partner by now, but it's obvious that a lot have been going on behind the scenes. So, the delay (in my mind) can be forgiven.
Now that these other mergers, etc. are out of the way, is it time for MNKD to make progress on the partner front? Or, do we still have to wait on the FDA?